Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

May 13, 2026 updated by: ECOG-ACRIN Cancer Research Group

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVE:

I. To determine if bortezomib, daratumumab and hyaluronidase-fihj (daratumumab), lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in minimal residual disease (MRD) positive patients.

SECONDARY OBJECTIVES:

I. To determine if Btz-DRd consolidation followed by DR maintenance after standard induction therapy with DRd results in superior overall survival compared to DRd consolidation followed by DR maintenance in MRD negative patients.

II. To determine if Btz-DRd consolidation followed by DR maintenance after standard induction therapy with DRd results in superior progression-free survival compared to DRd consolidation followed by DR maintenance in both MRD positive and MRD negative patients.

III. To describe and compare the incidence of toxicities during consolidation between Btz-DRd and DRd arms.

IV. To assess the improvement in MRD negative rate with consolidation among patients who are MRD positive after induction.

V. To assess the sustained MRD negative rate among patients who are MRD negative after induction.

PATIENT REPORTED OUTCOMES (PRO) OBJECTIVES:

I. To quantify the extent to which the addition of bortezomib to DRd over consolidation treatment contributes to neuropathy and associated physical and functional impairments. (Primary PRO Objective) II. To evaluate the rate of resolution of neurotoxicity and associated physical and functional impairments following completion of consolidation therapy. (Secondary PRO Objective) III. To investigate the relationship between MRD status and patient reported health-related quality of life outcomes. (Exploratory PRO Objective) IV. To evaluate attributes of select patient reported treatment-emergent symptomatic adverse events (PRO- Common Terminology Criteria for Adverse Events [CTCAE]) longitudinally and compare responses with provider-reported adverse events. (Exploratory PRO Objective) V. To tabulate PRO compliance and completion rates. (Exploratory PRO Objective)

IMAGING OBJECTIVES:

I. To evaluate the association between post-induction fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) and patient outcomes (overall survival [OS] and progression-free survival [PFS]). (Primary Imaging Objective) II. To evaluate the association between baseline 18F-FDG PET/CT and patient outcomes (PFS and OS). (Secondary Imaging Objective) III. To compare overall survival with the addition of Bortezomib to consolidation DRd therapy among 18F-FDG PET/CT-positive and 18F-FDG PET/CT-negative subgroups. (Secondary Imaging Objective) IV. To evaluate the ability of baseline 18F-FDG PET/CT to predict post-induction depth of response as measured by MRD assessment. (Secondary Imaging Objective) V. To evaluate the ability of post-induction 18F-FDG PET/CT to predict MRD conversion post-consolidation. (Secondary Imaging Objective) VI. To utilize 18F-FDG PET/CT, standard risk factors and clinical data to identify distinct subgroups with differing patient outcomes (PFS and OS). (Exploratory Imaging Objective) VII. To compare the various qualitative 18F-FDG PET/CT criteria to determine which criteria yields superior risk stratification. (Exploratory Imaging Objective)

OUTLINE:

ARM A (INDUCTION): All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.

After completion of standard induction therapy, patients are randomized to 1 of 2 arms.

ARM B:

CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM C:

CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months if less than 2 years from study entry, every 6 months if 2-5 years from study entry, then annually for up to 15 years from study entry.

Study Type

Interventional

Enrollment (Estimated)

1450

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Puerto Rico
      • Bayamón, Puerto Rico, 00961
        • Suspended
        • Puerto Rico Hematology Oncology Group
      • Bayamón, Puerto Rico, 00959-5060
        • Suspended
        • Cancer Center-Metro Medical Center Bayamon
      • Manati, Puerto Rico, 00674
        • Suspended
        • Doctors Cancer Center
      • San Juan, Puerto Rico, 00917
        • Suspended
        • San Juan Community Oncology Group
      • San Juan, Puerto Rico, 00927
        • Suspended
        • Centro Comprensivo de Cancer de UPR
      • San Juan, Puerto Rico, 00936
        • Suspended
        • San Juan City Hospital
      • San Juan, Puerto Rico, 00927
        • Suspended
        • PROncology
  • United States
    • Alaska
      • Anchorage, Alaska, United States, 98508
        • Suspended
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, United States, 99504
        • Suspended
        • Anchorage Radiation Therapy Center
      • Anchorage, Alaska, United States, 99508
        • Suspended
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, United States, 99508
        • Suspended
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, United States, 99508
        • Suspended
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, United States, 99508
        • Suspended
        • Anchorage Oncology Centre
      • Anchorage, Alaska, United States, 99508
        • Suspended
        • Katmai Oncology Group
      • Anchorage, Alaska, United States, 99508
        • Suspended
        • Providence Alaska Medical Center
    • Arizona
      • Phoenix, Arizona, United States, 85004
      • Tucson, Arizona, United States, 85704
        • Suspended
        • University of Arizona Cancer Center-Orange Grove Campus
      • Tucson, Arizona, United States, 85719
        • Suspended
        • Banner University Medical Center - Tucson
      • Tucson, Arizona, United States, 85719
        • Suspended
        • University of Arizona Cancer Center-North Campus
    • Arkansas
      • Fort Smith, Arkansas, United States, 72903
        • Recruiting
        • Mercy Hospital Fort Smith
        • Contact:
          • Site Public Contact
          • Phone Number: 800-378-9373
        • Principal Investigator:
          • Jay W. Carlson
      • Hot Springs, Arkansas, United States, 71913
        • Suspended
        • CHI Saint Vincent Cancer Center Hot Springs
      • Little Rock, Arkansas, United States, 72205
        • Recruiting
        • CARTI Cancer Center
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Little Rock, Arkansas, United States, 72205
        • Suspended
        • John L McClellan Memorial Veterans Hospital
    • California
      • Arroyo Grande, California, United States, 93420
      • Auburn, California, United States, 95603
        • Suspended
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
      • Auburn, California, United States, 95602
        • Suspended
        • Sutter Auburn Faith Hospital
      • Berkeley, California, United States, 94704
        • Suspended
        • Alta Bates Summit Medical Center-Herrick Campus
      • Burbank, California, United States, 91505
        • Suspended
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Burlingame, California, United States, 94010
        • Suspended
        • Mills-Peninsula Medical Center
      • Cameron Park, California, United States, 95682
        • Suspended
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
      • Carmichael, California, United States, 95608
        • Recruiting
        • Mercy San Juan Medical Center
        • Principal Investigator:
          • Shahzad Siddique
        • Contact:
      • Carmichael, California, United States, 95608
      • Castro Valley, California, United States, 94546
        • Suspended
        • Eden Hospital Medical Center
      • Davis, California, United States, 95616
        • Suspended
        • Sutter Davis Hospital
      • Elk Grove, California, United States, 95758
      • Fremont, California, United States, 94538
        • Suspended
        • Palo Alto Medical Foundation-Fremont
      • Fremont, California, United States, 94538
        • Suspended
        • Washington Hospital
      • Merced, California, United States, 95340
      • Modesto, California, United States, 95355
        • Suspended
        • Memorial Medical Center
      • Mountain View, California, United States, 94040
        • Suspended
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • Mountain View, California, United States, 94040
        • Suspended
        • Palo Alto Medical Foundation-Camino Division
      • Novato, California, United States, 94945
        • Suspended
        • Sutter Cancer Research Consortium
      • Palo Alto, California, United States, 94301
        • Suspended
        • Palo Alto Medical Foundation Health Care
      • Rocklin, California, United States, 95765
      • Roseville, California, United States, 95661
        • Suspended
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
      • Roseville, California, United States, 95661
        • Suspended
        • Sutter Roseville Medical Center
      • Sacramento, California, United States, 95816
      • Sacramento, California, United States, 95816
        • Suspended
        • Sutter Medical Center Sacramento
      • San Francisco, California, United States, 94115
        • Suspended
        • California Pacific Medical Center-Pacific Campus
      • San Luis Obispo, California, United States, 93401
      • San Mateo, California, United States, 94401
        • Suspended
        • Mills Health Center
      • Santa Barbara, California, United States, 93105
        • Suspended
        • Ridley-Tree Cancer Center
      • Santa Cruz, California, United States, 95065
        • Suspended
        • Palo Alto Medical Foundation-Santa Cruz
      • Santa Cruz, California, United States, 95065
        • Suspended
        • Santa Cruz Radiation Oncology Medical Group
      • Santa Maria, California, United States, 93444
      • Santa Rosa, California, United States, 95403
        • Suspended
        • Sutter Pacific Medical Foundation
      • Stockton, California, United States, 95204
        • Recruiting
        • Saint Joseph's Medical Center
        • Contact:
          • Site Public Contact
          • Phone Number: 209-461-5257
        • Principal Investigator:
          • Shahzad Siddique
      • Sunnyvale, California, United States, 94086
        • Suspended
        • Palo Alto Medical Foundation-Sunnyvale
      • Vallejo, California, United States, 94589
        • Suspended
        • Sutter Solano Medical Center/Cancer Center
      • Woodland, California, United States, 95695
    • Colorado
      • Colorado Springs, Colorado, United States, 80907
      • Colorado Springs, Colorado, United States, 80907
      • Colorado Springs, Colorado, United States, 80923
      • Denver, Colorado, United States, 80210
        • Suspended
        • AdventHealth Porter
      • Durango, Colorado, United States, 81301
        • Suspended
        • Mercy Medical Center
      • Durango, Colorado, United States, 81301
        • Suspended
        • CommonSpirit Cancer Center Mercy
      • Lakewood, Colorado, United States, 80228
      • Littleton, Colorado, United States, 80122
        • Suspended
        • AdventHealth Littleton
      • Longmont, Colorado, United States, 80501
        • Suspended
        • Longmont United Hospital
      • Longmont, Colorado, United States, 80501
        • Suspended
        • Rocky Mountain Cancer Centers-Longmont
      • Parker, Colorado, United States, 80138
        • Suspended
        • AdventHealth Parker
      • Pueblo, Colorado, United States, 81004
      • Westminster, Colorado, United States, 80023
    • Connecticut
      • Derby, Connecticut, United States, 06418
        • Suspended
        • Smilow Cancer Hospital-Derby Care Center
      • Fairfield, Connecticut, United States, 06824
        • Suspended
        • Smilow Cancer Hospital Care Center-Fairfield
      • Glastonbury, Connecticut, United States, 06033
        • Suspended
        • Smilow Cancer Hospital Care Center at Glastonbury
      • Greenwich, Connecticut, United States, 06830
        • Suspended
        • Smilow Cancer Hospital Care Center at Greenwich
      • Guilford, Connecticut, United States, 06437
        • Suspended
        • Smilow Cancer Hospital Care Center - Guilford
      • Hartford, Connecticut, United States, 06102
        • Suspended
        • Hartford Hospital
      • Hartford, Connecticut, United States, 06105
        • Suspended
        • Smilow Cancer Hospital Care Center at Saint Francis
      • Meriden, Connecticut, United States, 06451
        • Suspended
        • Midstate Medical Center
      • New Britain, Connecticut, United States, 06050
        • Suspended
        • The Hospital of Central Connecticut
      • New Haven, Connecticut, United States, 06510
        • Suspended
        • Smilow Cancer Center/Yale-New Haven Hospital
      • New Haven, Connecticut, United States, 06520
        • Suspended
        • Yale University
      • North Haven, Connecticut, United States, 06473
        • Suspended
        • Yale-New Haven Hospital North Haven Medical Center
      • Orange, Connecticut, United States, 06477
        • Suspended
        • Smilow Cancer Hospital-Orange Care Center
      • Torrington, Connecticut, United States, 06790
        • Suspended
        • Smilow Cancer Hospital-Torrington Care Center
      • Trumbull, Connecticut, United States, 06611
        • Suspended
        • Smilow Cancer Hospital Care Center-Trumbull
      • Waterbury, Connecticut, United States, 06708
        • Suspended
        • Smilow Cancer Hospital-Waterbury Care Center
      • Waterford, Connecticut, United States, 06385
        • Suspended
        • Smilow Cancer Hospital Care Center - Waterford
    • Delaware
      • Lewes, Delaware, United States, 19958
        • Active, not recruiting
        • Beebe Medical Center
      • Millville, Delaware, United States, 19967
        • Active, not recruiting
        • Beebe South Coastal Health Campus
      • Newark, Delaware, United States, 19713
        • Active, not recruiting
        • Helen F Graham Cancer Center
      • Newark, Delaware, United States, 19713
        • Active, not recruiting
        • Medical Oncology Hematology Consultants PA
      • Newark, Delaware, United States, 19713
        • Active, not recruiting
        • Delaware Clinical and Laboratory Physicians PA
      • Newark, Delaware, United States, 19718
        • Active, not recruiting
        • Christiana Care Health System-Christiana Hospital
      • Rehoboth Beach, Delaware, United States, 19971
        • Active, not recruiting
        • Beebe Health Campus
      • Seaford, Delaware, United States, 19973
        • Suspended
        • TidalHealth Nanticoke / Allen Cancer Center
      • Wilmington, Delaware, United States, 19801
        • Active, not recruiting
        • Christiana Care Health System-Wilmington Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20016
        • Suspended
        • Sibley Memorial Hospital
    • Florida
      • Fort Lauderdale, Florida, United States, 33308
      • Jacksonville, Florida, United States, 32209
        • Suspended
        • University of Florida Health Science Center - Jacksonville
      • Pensacola, Florida, United States, 32504
        • Suspended
        • Sacred Heart Hospital
    • Idaho
      • Boise, Idaho, United States, 83706
        • Recruiting
        • Saint Alphonsus Cancer Care Center-Boise
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Boise, Idaho, United States, 83712
        • Suspended
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, United States, 83605
        • Recruiting
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Coeur d'Alene, Idaho, United States, 83814
        • Suspended
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, United States, 83617
        • Suspended
        • Walter Knox Memorial Hospital
      • Fruitland, Idaho, United States, 83619
        • Suspended
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, United States, 83642
        • Suspended
        • Idaho Urologic Institute-Meridian
      • Meridian, Idaho, United States, 83642
        • Suspended
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, United States, 83687
        • Recruiting
        • Saint Alphonsus Cancer Care Center-Nampa
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Nampa, Idaho, United States, 83687
        • Suspended
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, United States, 83854
        • Suspended
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, United States, 83864
        • Suspended
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, United States, 83301
        • Suspended
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Alton, Illinois, United States, 62002
        • Recruiting
        • OSF Saint Anthony's Health Center
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 618-463-5623
      • Aurora, Illinois, United States, 60504
        • Suspended
        • Rush-Copley Medical Center
      • Aurora, Illinois, United States, 60506
        • Suspended
        • Advocate Outpatient Center - Aurora
      • Barrington, Illinois, United States, 60010
        • Suspended
        • Advocate Good Shepherd Hospital
      • Bloomington, Illinois, United States, 61704
        • Recruiting
        • Illinois CancerCare-Bloomington
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Burr Ridge, Illinois, United States, 60527
        • Suspended
        • Loyola Center for Health at Burr Ridge
      • Canton, Illinois, United States, 61520
        • Recruiting
        • Illinois CancerCare-Canton
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Carbondale, Illinois, United States, 62902
        • Recruiting
        • Memorial Hospital of Carbondale
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Carterville, Illinois, United States, 62918
        • Recruiting
        • SIH Cancer Institute
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Carthage, Illinois, United States, 62321
        • Recruiting
        • Illinois CancerCare-Carthage
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Centralia, Illinois, United States, 62801
        • Recruiting
        • Centralia Oncology Clinic
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Centralia, Illinois, United States, 62801
        • Suspended
        • Saint Mary's Hospital
      • Chicago, Illinois, United States, 60612
        • Active, not recruiting
        • University of Illinois
      • Chicago, Illinois, United States, 60657
        • Suspended
        • Advocate Illinois Masonic Medical Center
      • Chicago, Illinois, United States, 60612
        • Suspended
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, United States, 60608
        • Suspended
        • Mount Sinai Hospital Medical Center
      • Crystal Lake, Illinois, United States, 60014
        • Suspended
        • AMG Crystal Lake - Oncology
      • Danville, Illinois, United States, 61832
        • Suspended
        • Carle at The Riverfront
      • DeKalb, Illinois, United States, 60115
        • Recruiting
        • Northwestern Medicine Cancer Center Kishwaukee
        • Contact:
        • Principal Investigator:
          • Renee Cheng
      • Decatur, Illinois, United States, 62526
        • Recruiting
        • Cancer Care Specialists of Illinois - Decatur
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Decatur, Illinois, United States, 62526
        • Recruiting
        • Decatur Memorial Hospital
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Dixon, Illinois, United States, 61021
        • Recruiting
        • Illinois CancerCare-Dixon
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 815-285-7800
      • Downers Grove, Illinois, United States, 60515
        • Suspended
        • Advocate Good Samaritan Hospital
      • Effingham, Illinois, United States, 62401
        • Recruiting
        • Crossroads Cancer Center
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Effingham, Illinois, United States, 62401
        • Suspended
        • Carle Physician Group-Effingham
      • Elgin, Illinois, United States, 60123
        • Suspended
        • Advocate Sherman Hospital
      • Eureka, Illinois, United States, 61530
        • Recruiting
        • Illinois CancerCare-Eureka
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Galesburg, Illinois, United States, 61401
        • Recruiting
        • Illinois CancerCare-Galesburg
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Galesburg, Illinois, United States, 61401
        • Suspended
        • Western Illinois Cancer Treatment Center
      • Geneva, Illinois, United States, 60134
        • Recruiting
        • Northwestern Medicine Cancer Center Delnor
        • Contact:
        • Principal Investigator:
          • Renee Cheng
      • Hazel Crest, Illinois, United States, 60429
        • Suspended
        • Advocate South Suburban Hospital
      • Homer Glen, Illinois, United States, 60491
        • Suspended
        • Loyola Medicine Homer Glen
      • Kewanee, Illinois, United States, 61443
        • Recruiting
        • Illinois CancerCare-Kewanee Clinic
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Libertyville, Illinois, United States, 60048
        • Suspended
        • AMG Libertyville - Oncology
      • Libertyville, Illinois, United States, 60048
        • Suspended
        • Condell Memorial Hospital
      • Macomb, Illinois, United States, 61455
        • Recruiting
        • Illinois CancerCare-Macomb
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Mattoon, Illinois, United States, 61938
        • Suspended
        • Carle Physician Group-Mattoon/Charleston
      • Maywood, Illinois, United States, 60153
        • Suspended
        • Loyola University Medical Center
      • Melrose Park, Illinois, United States, 60160
        • Suspended
        • Marjorie Weinberg Cancer Center at Loyola-Gottlieb
      • Mount Vernon, Illinois, United States, 62864
        • Recruiting
        • SSM Health Good Samaritan
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Normal, Illinois, United States, 61761
        • Suspended
        • Carle Cancer Institute Normal
      • Normal, Illinois, United States, 61761
        • Suspended
        • Carle BroMenn Medical Center
      • O'Fallon, Illinois, United States, 62269
        • Recruiting
        • Cancer Care Center of O'Fallon
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • O'Fallon, Illinois, United States, 62269
        • Recruiting
        • HSHS Saint Elizabeth's Hospital
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Oak Lawn, Illinois, United States, 60453-2699
        • Suspended
        • Advocate Christ Medical Center
      • Ottawa, Illinois, United States, 61350
        • Recruiting
        • Illinois CancerCare-Ottawa Clinic
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Park Ridge, Illinois, United States, 60068
        • Suspended
        • Advocate Lutheran General Hospital
      • Pekin, Illinois, United States, 61554
        • Recruiting
        • Illinois CancerCare-Pekin
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Peoria, Illinois, United States, 61615
        • Recruiting
        • Illinois CancerCare-Peoria
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Peoria, Illinois, United States, 61636
        • Recruiting
        • Methodist Medical Center of Illinois
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Peru, Illinois, United States, 61354
        • Recruiting
        • Illinois CancerCare-Peru
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Peru, Illinois, United States, 61354
        • Recruiting
        • Valley Radiation Oncology
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 815-664-4141
      • Princeton, Illinois, United States, 61356
        • Recruiting
        • Illinois CancerCare-Princeton
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Rockford, Illinois, United States, 61114
        • Suspended
        • UW Health Carbone Cancer Center Rockford
      • Springfield, Illinois, United States, 62702
        • Recruiting
        • Southern Illinois University School of Medicine
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 217-545-7929
      • Springfield, Illinois, United States, 62702
        • Recruiting
        • Springfield Clinic
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 800-444-7541
      • Springfield, Illinois, United States, 62781
        • Recruiting
        • Springfield Memorial Hospital
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
      • Urbana, Illinois, United States, 61801
        • Suspended
        • The Carle Foundation Hospital
      • Urbana, Illinois, United States, 61801
        • Suspended
        • Carle Cancer Center
      • Warrenville, Illinois, United States, 60555
        • Recruiting
        • Northwestern Medicine Cancer Center Warrenville
        • Contact:
        • Principal Investigator:
          • Renee Cheng
      • Washington, Illinois, United States, 61571
        • Recruiting
        • Illinois CancerCare - Washington
        • Contact:
        • Principal Investigator:
          • Bryan A. Faller
      • Yorkville, Illinois, United States, 60560
        • Suspended
        • Rush-Copley Healthcare Center
    • Indiana
      • Carmel, Indiana, United States, 46032
        • Not yet recruiting
        • IU Health North Hospital
        • Contact:
        • Principal Investigator:
          • Rafat Abonour
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Indiana University/Melvin and Bren Simon Cancer Center
        • Contact:
        • Principal Investigator:
          • Rafat Abonour
      • Indianapolis, Indiana, United States, 46202
        • Not yet recruiting
        • IU Health Methodist Hospital
        • Contact:
        • Principal Investigator:
          • Rafat Abonour
      • Richmond, Indiana, United States, 47374
        • Suspended
        • Reid Health
    • Iowa
      • Ames, Iowa, United States, 50010
        • Recruiting
        • Mary Greeley Medical Center
        • Principal Investigator:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Phone Number: 515-956-4132
      • Ames, Iowa, United States, 50010
        • Recruiting
        • McFarland Clinic - Ames
        • Principal Investigator:
          • Joseph J. Merchant
        • Contact:
      • Ankeny, Iowa, United States, 50023
        • Recruiting
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Boone, Iowa, United States, 50036
        • Suspended
        • McFarland Clinic - Boone
      • Carroll, Iowa, United States, 51401
        • Recruiting
        • Saint Anthony Regional Hospital
        • Contact:
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Cedar Rapids, Iowa, United States, 52403
        • Recruiting
        • Mercy Hospital
        • Contact:
          • Site Public Contact
          • Phone Number: 319-365-4673
        • Principal Investigator:
          • Deborah W. Wilbur
      • Cedar Rapids, Iowa, United States, 52403
        • Recruiting
        • Oncology Associates at Mercy Medical Center
        • Principal Investigator:
          • Deborah W. Wilbur
        • Contact:
          • Site Public Contact
          • Phone Number: 319-363-2690
      • Clive, Iowa, United States, 50325
        • Recruiting
        • Mercy Cancer Center-West Lakes
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Richard L. Deming
      • Clive, Iowa, United States, 50325
        • Recruiting
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Council Bluffs, Iowa, United States, 51503
        • Suspended
        • Alegent Health Mercy Hospital
      • Creston, Iowa, United States, 50801
        • Recruiting
        • Greater Regional Medical Center
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Richard L. Deming
      • Des Moines, Iowa, United States, 50314
        • Recruiting
        • Broadlawns Medical Center
        • Contact:
          • Site Public Contact
          • Phone Number: 515-282-2200
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, United States, 50314
        • Recruiting
        • Mercy Medical Center - Des Moines
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Richard L. Deming
      • Des Moines, Iowa, United States, 50309
        • Recruiting
        • Iowa Methodist Medical Center
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-6727
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, United States, 50316
        • Recruiting
        • Iowa Lutheran Hospital
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-8704
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, United States, 50309
        • Recruiting
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, United States, 50314
        • Recruiting
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, United States, 50501
        • Recruiting
        • McFarland Clinic - Trinity Cancer Center
        • Principal Investigator:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Phone Number: 515-956-4132
      • Fort Dodge, Iowa, United States, 50501
        • Recruiting
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
        • Principal Investigator:
          • Seema Harichand-Herdt
        • Contact:
      • Jefferson, Iowa, United States, 50129
        • Suspended
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, United States, 50158
        • Recruiting
        • McFarland Clinic - Marshalltown
        • Principal Investigator:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Phone Number: 515-956-4132
      • Sioux City, Iowa, United States, 51101
        • Active, not recruiting
        • Siouxland Regional Cancer Center
      • Waukee, Iowa, United States, 50263
        • Recruiting
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Seema Harichand-Herdt
      • West Des Moines, Iowa, United States, 50266
        • Recruiting
        • Mercy Medical Center-West Lakes
        • Contact:
          • Site Public Contact
          • Phone Number: 515-241-3305
        • Principal Investigator:
          • Richard L. Deming
      • West Des Moines, Iowa, United States, 50266-7700
        • Recruiting
        • Methodist West Hospital
        • Contact:
          • Site Public Contact
          • Phone Number: 515-343-1000
        • Principal Investigator:
          • Seema Harichand-Herdt
    • Kansas
      • Chanute, Kansas, United States, 66720
        • Suspended
        • Cancer Center of Kansas - Chanute
      • Dodge City, Kansas, United States, 67801
        • Suspended
        • Cancer Center of Kansas - Dodge City
      • El Dorado, Kansas, United States, 67042
        • Suspended
        • Cancer Center of Kansas - El Dorado
      • Garden City, Kansas, United States, 67846
        • Recruiting
        • Central Care Cancer Center - Garden City
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Great Bend, Kansas, United States, 67530
        • Recruiting
        • Central Care Cancer Center - Great Bend
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Independence, Kansas, United States, 67301
        • Suspended
        • Cancer Center of Kansas-Independence
      • Kingman, Kansas, United States, 67068
        • Suspended
        • Cancer Center of Kansas-Kingman
      • Liberal, Kansas, United States, 67905
        • Suspended
        • Cancer Center of Kansas-Liberal
      • Manhattan, Kansas, United States, 66502
        • Suspended
        • Cancer Center of Kansas-Manhattan
      • McPherson, Kansas, United States, 67460
        • Suspended
        • Cancer Center of Kansas - McPherson
      • Newton, Kansas, United States, 67114
        • Suspended
        • Cancer Center of Kansas - Newton
      • Parsons, Kansas, United States, 67357
        • Suspended
        • Cancer Center of Kansas - Parsons
      • Pittsburg, Kansas, United States, 66762
        • Recruiting
        • Mercy Hospital Pittsburg
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 888-446-3729
      • Pratt, Kansas, United States, 67124
        • Suspended
        • Cancer Center of Kansas - Pratt
      • Salina, Kansas, United States, 67401
        • Suspended
        • Cancer Center of Kansas - Salina
      • Wellington, Kansas, United States, 67152
        • Suspended
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, United States, 67208
        • Suspended
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, United States, 67214
        • Suspended
        • Ascension Via Christi Hospitals Wichita
      • Wichita, Kansas, United States, 67214
        • Suspended
        • Cancer Center of Kansas - Wichita
      • Winfield, Kansas, United States, 67156
        • Suspended
        • Cancer Center of Kansas - Winfield
    • Kentucky
      • Bardstown, Kentucky, United States, 40004
      • Corbin, Kentucky, United States, 40701
      • Lexington, Kentucky, United States, 40509
      • Lexington, Kentucky, United States, 40504
      • Lexington, Kentucky, United States, 40504
        • Suspended
        • Saint Joseph Hospital
      • London, Kentucky, United States, 40741
      • Louisville, Kentucky, United States, 40202
        • Suspended
        • Jewish Hospital
      • Louisville, Kentucky, United States, 40215
        • Suspended
        • Saints Mary and Elizabeth Hospital
      • Louisville, Kentucky, United States, 40245
        • Suspended
        • UofL Health Medical Center Northeast
      • Mount Sterling, Kentucky, United States, 40353
      • Shepherdsville, Kentucky, United States, 40165
        • Suspended
        • Jewish Hospital Medical Center South
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70805
        • Suspended
        • LSU Health Baton Rouge-North Clinic
      • Baton Rouge, Louisiana, United States, 70808
        • Suspended
        • Our Lady of the Lake Physician Group
      • Monroe, Louisiana, United States, 71202
        • Suspended
        • Ochsner LSU Health Monroe Medical Center
      • Shreveport, Louisiana, United States, 71103
        • Suspended
        • LSU Health Sciences Center at Shreveport
    • Maryland
      • Elkton, Maryland, United States, 21921
        • Active, not recruiting
        • Christiana Care - Union Hospital
      • Frederick, Maryland, United States, 21701
        • Active, not recruiting
        • Frederick Memorial Hospital
      • Frederick, Maryland, United States, 21702
        • Active, not recruiting
        • FMH James M Stockman Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, United States, 02111
      • Stoneham, Massachusetts, United States, 02180
        • Recruiting
        • Tufts Medical Center Cancer Center Stoneham
        • Principal Investigator:
          • Raymond L. Comenzo
        • Contact:
    • Michigan
      • Adrian, Michigan, United States, 49221
        • Suspended
        • Hickman Cancer Center
      • Alma, Michigan, United States, 48801
        • Recruiting
        • MyMichigan Medical Center Gratiot
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Alpena, Michigan, United States, 49707
        • Recruiting
        • MyMichigan Medical Center Alpena
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Ann Arbor, Michigan, United States, 48106
        • Recruiting
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Battle Creek, Michigan, United States, 49017
        • Suspended
        • Bronson Battle Creek
      • Brighton, Michigan, United States, 48114
        • Recruiting
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Brighton, Michigan, United States, 48114
      • Canton, Michigan, United States, 48188
        • Recruiting
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Canton, Michigan, United States, 48188
      • Caro, Michigan, United States, 48723
        • Suspended
        • Caro Cancer Center
      • Chelsea, Michigan, United States, 48118
        • Recruiting
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Chelsea, Michigan, United States, 48118
      • Clarkston, Michigan, United States, 48346
      • Clarkston, Michigan, United States, 48346
      • Detroit, Michigan, United States, 48202
        • Suspended
        • Henry Ford Hospital
      • Detroit, Michigan, United States, 48236
        • Recruiting
        • Henry Ford Health Saint John Hospital
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • East China Township, Michigan, United States, 48054
        • Recruiting
        • Henry Ford River District Hospital
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Escanaba, Michigan, United States, 49829
        • Recruiting
        • OSF Saint Francis Hospital and Medical Group
        • Principal Investigator:
          • Brian L. Burnette
        • Contact:
      • Flint, Michigan, United States, 48503
        • Recruiting
        • Genesee Hematology Oncology PC
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Flint, Michigan, United States, 48503
        • Recruiting
        • Genesys Hurley Cancer Institute
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Flint, Michigan, United States, 48503
        • Recruiting
        • Hurley Medical Center
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Flint, Michigan, United States, 48503
        • Recruiting
        • Cancer Hematology Centers - Flint
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Gladwin, Michigan, United States, 48624
        • Recruiting
        • MyMichigan Medical Center Gladwin
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Grand Rapids, Michigan, United States, 49503
        • Suspended
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, United States, 49503
        • Suspended
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Grand Rapids, Michigan, United States, 49503
        • Suspended
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Grosse Pointe Woods, Michigan, United States, 48236
        • Recruiting
        • Henry Ford Saint John Hospital - Breast
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Grosse Pointe Woods, Michigan, United States, 48236
        • Recruiting
        • Henry Ford Saint John Hospital - Academic
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Grosse Pointe Woods, Michigan, United States, 48236
        • Recruiting
        • Henry Ford Saint John Hospital - Van Elslander
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Kalamazoo, Michigan, United States, 49007
        • Suspended
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, United States, 49007
        • Suspended
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, United States, 49048
        • Suspended
        • Beacon Kalamazoo
      • Kalamazoo, Michigan, United States, 49009
        • Suspended
        • Beacon Kalamazoo Cancer Center
      • Lansing, Michigan, United States, 48912
        • Recruiting
        • University of Michigan Health - Sparrow Lansing
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Livonia, Michigan, United States, 48154
        • Suspended
        • Hope Cancer Clinic
      • Livonia, Michigan, United States, 48154
        • Recruiting
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Macomb, Michigan, United States, 48044
        • Recruiting
        • Henry Ford Warren Hospital - Breast Macomb
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Macomb, Michigan, United States, 48044
        • Recruiting
        • Henry Ford Saint John Hospital - Macomb Medical
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Marlette, Michigan, United States, 48453
        • Suspended
        • Saint Mary's Oncology/Hematology Associates of Marlette
      • Midland, Michigan, United States, 48670
        • Recruiting
        • MyMichigan Medical Center Midland
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Monroe, Michigan, United States, 48162
        • Suspended
        • Toledo Clinic Cancer Centers-Monroe
      • Mount Pleasant, Michigan, United States, 48858
        • Recruiting
        • MyMichigan Medical Center Mount Pleasant
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Muskegon, Michigan, United States, 49444
        • Suspended
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, United States, 49120
        • Suspended
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, United States, 49444
        • Suspended
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Novi, Michigan, United States, 48374
        • Suspended
        • Henry Ford Health Providence Novi Hospital
      • Pontiac, Michigan, United States, 48341
      • Pontiac, Michigan, United States, 48341
      • Pontiac, Michigan, United States, 48341
        • Recruiting
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Pontiac, Michigan, United States, 48341
        • Recruiting
        • Michigan Healthcare Professionals Pontiac
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Reed City, Michigan, United States, 49677
        • Suspended
        • Corewell Health Reed City Hospital
      • Rochester Hills, Michigan, United States, 48309
        • Suspended
        • Henry Ford Rochester Hospital
      • Saginaw, Michigan, United States, 48604
        • Suspended
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, United States, 48601
      • Saint Joseph, Michigan, United States, 49085
        • Suspended
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, United States, 49085
        • Suspended
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Southfield, Michigan, United States, 48075
        • Suspended
        • Henry Ford Health Providence Southfield Hospital
      • Sterling Heights, Michigan, United States, 48312
        • Suspended
        • Bhadresh Nayak MD PC-Sterling Heights
      • Tawas City, Michigan, United States, 48764
      • Traverse City, Michigan, United States, 49684
        • Suspended
        • Munson Medical Center
      • Warren, Michigan, United States, 48088
        • Suspended
        • Advanced Breast Care Center PLLC
      • Warren, Michigan, United States, 48093
        • Suspended
        • Macomb Hematology Oncology PC
      • Warren, Michigan, United States, 48093
        • Recruiting
        • Henry Ford Madison Heights Hospital - Breast
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Warren, Michigan, United States, 48093
        • Recruiting
        • Henry Ford Health Warren Hospital
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • Warren, Michigan, United States, 48093
        • Recruiting
        • Henry Ford Warren Hospital - GLCMS
        • Principal Investigator:
          • Elie G. Dib
        • Contact:
      • West Branch, Michigan, United States, 48661
        • Suspended
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Wyoming, Michigan, United States, 49519
        • Suspended
        • University of Michigan Health - West
      • Ypsilanti, Michigan, United States, 48106
      • Ypsilanti, Michigan, United States, 48197
        • Recruiting
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
    • Minnesota
      • Bemidji, Minnesota, United States, 56601
        • Suspended
        • Sanford Joe Lueken Cancer Center
      • Burnsville, Minnesota, United States, 55337
        • Recruiting
        • Minnesota Oncology - Burnsville
        • Contact:
        • Principal Investigator:
          • David M. King
      • Burnsville, Minnesota, United States, 55337
        • Suspended
        • Fairview Ridges Hospital
      • Cambridge, Minnesota, United States, 55008
        • Recruiting
        • Cambridge Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Chaska, Minnesota, United States, 55318
        • Recruiting
        • Minnesota Oncology Hematology PA-Chaska
        • Contact:
        • Principal Investigator:
          • David M. King
      • Coon Rapids, Minnesota, United States, 55433
        • Recruiting
        • Mercy Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Coon Rapids, Minnesota, United States, 55433
        • Recruiting
        • Minnesota Oncology - Coon Rapids
        • Contact:
        • Principal Investigator:
          • David M. King
      • Edina, Minnesota, United States, 55435
        • Recruiting
        • Fairview Southdale Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Edina, Minnesota, United States, 55435
        • Recruiting
        • Minnesota Oncology - Edina
        • Contact:
        • Principal Investigator:
          • David M. King
      • Fridley, Minnesota, United States, 55432
        • Active, not recruiting
        • Unity Hospital
      • Maple Grove, Minnesota, United States, 55369
        • Recruiting
        • Fairview Clinics and Surgery Center Maple Grove
        • Contact:
        • Principal Investigator:
          • David M. King
      • Maple Grove, Minnesota, United States, 55369
        • Recruiting
        • Minnesota Oncology - Maple Grove
        • Principal Investigator:
          • David M. King
        • Contact:
      • Maplewood, Minnesota, United States, 55109
        • Recruiting
        • Minnesota Oncology Hematology PA-Maplewood
        • Contact:
        • Principal Investigator:
          • David M. King
      • Maplewood, Minnesota, United States, 55109
        • Recruiting
        • Saint John's Hospital - Healtheast
        • Contact:
        • Principal Investigator:
          • David M. King
      • Minneapolis, Minnesota, United States, 55407
        • Recruiting
        • Abbott-Northwestern Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Minneapolis, Minnesota, United States, 55415
        • Recruiting
        • Hennepin County Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Minneapolis, Minnesota, United States, 55454
        • Suspended
        • Health Partners Inc
      • Monticello, Minnesota, United States, 55362
        • Recruiting
        • Monticello Cancer Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • New Ulm, Minnesota, United States, 56073
        • Recruiting
        • New Ulm Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Princeton, Minnesota, United States, 55371
        • Recruiting
        • Fairview Northland Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Robbinsdale, Minnesota, United States, 55422
        • Recruiting
        • North Memorial Medical Health Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinic in Rochester
        • Principal Investigator:
          • Shaji K. Kumar
        • Contact:
          • Site Public Contact
          • Phone Number: 855-776-0015
      • Saint Cloud, Minnesota, United States, 56303
        • Suspended
        • Coborn Cancer Center at Saint Cloud Hospital
      • Saint Louis Park, Minnesota, United States, 55416
        • Recruiting
        • Park Nicollet Clinic - Saint Louis Park
        • Contact:
        • Principal Investigator:
          • David M. King
      • Saint Paul, Minnesota, United States, 55101
        • Recruiting
        • Regions Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Saint Paul, Minnesota, United States, 55102
        • Recruiting
        • United Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Shakopee, Minnesota, United States, 55379
        • Recruiting
        • Saint Francis Regional Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Stillwater, Minnesota, United States, 55082
        • Recruiting
        • Lakeview Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Thief River Falls, Minnesota, United States, 56701
        • Suspended
        • Sanford Thief River Falls Medical Center
      • Waconia, Minnesota, United States, 55387
        • Recruiting
        • Ridgeview Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
      • Willmar, Minnesota, United States, 56201
        • Recruiting
        • Rice Memorial Hospital
        • Contact:
        • Principal Investigator:
          • David M. King
      • Woodbury, Minnesota, United States, 55125
        • Recruiting
        • Minnesota Oncology Hematology PA-Woodbury
        • Contact:
        • Principal Investigator:
          • David M. King
      • Wyoming, Minnesota, United States, 55092
        • Recruiting
        • Fairview Lakes Medical Center
        • Contact:
        • Principal Investigator:
          • David M. King
    • Mississippi
      • Gulfport, Mississippi, United States, 39502
        • Suspended
        • Gulfport Memorial Hospital
    • Missouri
      • Ballwin, Missouri, United States, 63011
        • Recruiting
        • Mercy Oncology and Hematology - Clayton-Clarkson
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 888-446-3729
      • Bolivar, Missouri, United States, 65613
        • Recruiting
        • Central Care Cancer Center - Bolivar
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Branson, Missouri, United States, 65616
        • Recruiting
        • Cox Cancer Center Branson
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 417-269-4520
      • Cape Girardeau, Missouri, United States, 63703
        • Recruiting
        • Saint Francis Medical Center
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 573-334-2230
          • Email: sfmc@sfmc.net
      • Cape Girardeau, Missouri, United States, 63703
        • Recruiting
        • Mercy Cancer Center - Cape Girardeau
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 888-446-3729
      • Chesterfield, Missouri, United States, 63017
        • Suspended
        • Saint Luke's Hospital
      • Farmington, Missouri, United States, 63640
        • Recruiting
        • Parkland Health Center - Farmington
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 314-996-5569
      • Jefferson City, Missouri, United States, 65109
        • Suspended
        • MU Health Care Goldschmidt Cancer Center
      • Joplin, Missouri, United States, 64804
        • Recruiting
        • Freeman Health System
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Joplin, Missouri, United States, 64804
        • Recruiting
        • Mercy Hospital Joplin
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Kansas City, Missouri, United States, 64128
        • Suspended
        • Kansas City Veterans Affairs Medical Center
      • Osage Beach, Missouri, United States, 65065
        • Recruiting
        • Lake Regional Hospital
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Rolla, Missouri, United States, 65401
        • Recruiting
        • Mercy Clinic-Rolla-Cancer and Hematology
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 573-458-6379
      • Rolla, Missouri, United States, 65401
        • Recruiting
        • Phelps Health Delbert Day Cancer Institute
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Saint Joseph, Missouri, United States, 64506
        • Recruiting
        • Heartland Regional Medical Center
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • Sainte Genevieve, Missouri, United States, 63670
        • Recruiting
        • Sainte Genevieve County Memorial Hospital
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 314-996-5569
      • Springfield, Missouri, United States, 65804
        • Recruiting
        • Mercy Hospital Springfield
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 417-269-4520
      • Springfield, Missouri, United States, 65807
        • Recruiting
        • CoxHealth South Hospital
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 417-269-4520
      • St Louis, Missouri, United States, 63128
        • Recruiting
        • Mercy Hospital South
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
      • St Louis, Missouri, United States, 63141
        • Recruiting
        • Mercy Hospital Saint Louis
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 314-251-7066
      • St Louis, Missouri, United States, 63131
        • Recruiting
        • Missouri Baptist Medical Center
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 314-996-5569
      • St Louis, Missouri, United States, 63109
        • Recruiting
        • Mercy Infusion Center - Chippewa
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 888-446-3729
      • Sullivan, Missouri, United States, 63080
        • Recruiting
        • Missouri Baptist Sullivan Hospital
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 314-996-5569
      • Sunset Hills, Missouri, United States, 63127
        • Recruiting
        • BJC Outpatient Center at Sunset Hills
        • Principal Investigator:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Phone Number: 314-996-5569
      • Washington, Missouri, United States, 63090
        • Recruiting
        • Mercy Hospital Washington
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 636-390-1600
    • Montana
      • Anaconda, Montana, United States, 59711
        • Suspended
        • Community Hospital of Anaconda
      • Billings, Montana, United States, 59101
        • Suspended
        • Billings Clinic Cancer Center
      • Bozeman, Montana, United States, 59715
        • Suspended
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, United States, 59405
        • Suspended
        • Great Falls Clinic
      • Great Falls, Montana, United States, 59405
        • Suspended
        • Benefis Sletten Cancer Institute
      • Havre, Montana, United States, 59501
        • Suspended
        • Hi-Line Sletten Cancer Center
      • Helena, Montana, United States, 59601
        • Suspended
        • Benefis Helena Specialty Center
      • Kalispell, Montana, United States, 59901
        • Suspended
        • Logan Health Medical Center
      • Missoula, Montana, United States, 59802
        • Suspended
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, United States, 59804
        • Suspended
        • Community Medical Center
    • Nebraska
      • Grand Island, Nebraska, United States, 68803
      • Grand Island, Nebraska, United States, 68803
        • Suspended
        • Nebraska Cancer Specialists/Oncology Hematology West PC
      • Kearney, Nebraska, United States, 68847
      • Lincoln, Nebraska, United States, 68510
        • Suspended
        • Saint Elizabeth Regional Medical Center
      • Lincoln, Nebraska, United States, 68516
        • Active, not recruiting
        • Cancer Partners of Nebraska
      • Omaha, Nebraska, United States, 68131
        • Suspended
        • Creighton University Medical Center
      • Omaha, Nebraska, United States, 68122
      • Omaha, Nebraska, United States, 68124
      • Omaha, Nebraska, United States, 68130
      • Papillion, Nebraska, United States, 68046
        • Suspended
        • Midlands Community Hospital
    • New Jersey
      • Cherry Hill, New Jersey, United States, 08002
        • Suspended
        • Jefferson Cherry Hill Hospital
      • Englewood, New Jersey, United States, 07631
        • Suspended
        • Englewood Hospital and Medical Center
      • Morristown, New Jersey, United States, 07960
        • Suspended
        • Morristown Medical Center
      • Sewell, New Jersey, United States, 08080
        • Suspended
        • Sidney Kimmel Cancer Center Washington Township
      • Summit, New Jersey, United States, 07902
        • Suspended
        • Overlook Hospital
    • New Mexico
      • Albuquerque, New Mexico, United States, 87106
        • Suspended
        • University of New Mexico Cancer Center
    • New York
      • Auburn, New York, United States, 13021
        • Suspended
        • Hematology Oncology Associates of Central New York-Auburn
      • Binghamton, New York, United States, 13905
        • Suspended
        • Lourdes Hospital
      • Camillus, New York, United States, 13031
        • Suspended
        • Hematology Oncology Associates of CNY at Camillus
      • East Syracuse, New York, United States, 13057
        • Suspended
        • Hematology Oncology Associates of Central New York-East Syracuse
      • Glens Falls, New York, United States, 12801
        • Suspended
        • Glens Falls Hospital
      • Rochester, New York, United States, 14642
        • Recruiting
        • University of Rochester
        • Contact:
          • Site Public Contact
          • Phone Number: 585-275-5830
        • Principal Investigator:
          • Brea C. Lipe
      • Stony Brook, New York, United States, 11794
        • Active, not recruiting
        • Stony Brook University Medical Center
      • Syracuse, New York, United States, 13210
        • Suspended
        • State University of New York Upstate Medical University
      • Verona, New York, United States, 13478
        • Suspended
        • Upstate Cancer Center at Verona
      • West Islip, New York, United States, 11795
        • Active, not recruiting
        • Good Samaritan University Hospital
    • North Carolina
      • Clinton, North Carolina, United States, 28328
        • Recruiting
        • Southeastern Medical Oncology Center-Clinton
        • Contact:
        • Principal Investigator:
          • Samer S. Kasbari
      • Goldsboro, North Carolina, United States, 27534
        • Recruiting
        • Southeastern Medical Oncology Center-Goldsboro
        • Contact:
        • Principal Investigator:
          • Samer S. Kasbari
      • Greenville, North Carolina, United States, 27834
        • Suspended
        • East Carolina University
      • Jacksonville, North Carolina, United States, 28546
        • Recruiting
        • Southeastern Medical Oncology Center-Jacksonville
        • Principal Investigator:
          • Samer S. Kasbari
        • Contact:
      • Kenansville, North Carolina, United States, 28349
        • Active, not recruiting
        • ECU Health Oncology Kenansville
      • Kinston, North Carolina, United States, 28501
        • Active, not recruiting
        • ECU Health Oncology Kinston
      • Richlands, North Carolina, United States, 28574
        • Active, not recruiting
        • ECU Health Oncology Richlands
    • North Dakota
      • Bismarck, North Dakota, United States, 58501
        • Suspended
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, United States, 58103
        • Suspended
        • Sanford South University Medical Center
      • Fargo, North Dakota, United States, 58103
        • Suspended
        • Southpointe-Sanford Medical Center Fargo
      • Fargo, North Dakota, United States, 58104
        • Suspended
        • Sanford Medical Center Fargo
      • Fargo, North Dakota, United States, 58122
        • Suspended
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, United States, 58122
        • Suspended
        • Sanford Broadway Medical Center
    • Ohio
      • Athens, Ohio, United States, 45701
        • Recruiting
        • OhioHealth O'Bleness Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Beachwood, Ohio, United States, 44122
        • Active, not recruiting
        • UHHS-Chagrin Highlands Medical Center
      • Beavercreek, Ohio, United States, 45431
        • Suspended
        • Indu and Raj Soin Medical Center
      • Belpre, Ohio, United States, 45714
        • Suspended
        • Strecker Cancer Center-Belpre
      • Boardman, Ohio, United States, 44512
        • Suspended
        • Saint Elizabeth Boardman Hospital
      • Centerville, Ohio, United States, 45459
        • Suspended
        • Miami Valley Hospital South
      • Centerville, Ohio, United States, 45459
        • Suspended
        • Dayton Physicians LLC-Miami Valley South
      • Chardon, Ohio, United States, 44024
        • Active, not recruiting
        • Geauga Hospital
      • Chillicothe, Ohio, United States, 45601
        • Suspended
        • Adena Regional Medical Center
      • Cincinnati, Ohio, United States, 45236
        • Suspended
        • Oncology Hematology Care Inc-Kenwood
      • Cincinnati, Ohio, United States, 45220
      • Cincinnati, Ohio, United States, 45242
      • Cincinnati, Ohio, United States, 45247
      • Cincinnati, Ohio, United States, 45255
      • Cincinnati, Ohio, United States, 45219
        • Suspended
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, United States, 44109
        • Recruiting
        • MetroHealth Medical Center
        • Contact:
        • Principal Investigator:
          • Tamila L. Kindwall-Keller
      • Cleveland, Ohio, United States, 44106
        • Active, not recruiting
        • Case Western Reserve University
      • Cleveland, Ohio, United States, 44106
        • Suspended
        • Louis Stokes Cleveland VA medical Center
      • Columbus, Ohio, United States, 43214
        • Recruiting
        • Columbus Oncology and Hematology Associates Inc
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Columbus, Ohio, United States, 43214
        • Recruiting
        • Riverside Methodist Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Columbus, Ohio, United States, 43215
        • Recruiting
        • Grant Medical Center
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Columbus, Ohio, United States, 43228
        • Recruiting
        • Doctors Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Columbus, Ohio, United States, 43213
        • Suspended
        • Mount Carmel East Hospital
      • Columbus, Ohio, United States, 43222
        • Suspended
        • Mount Carmel Health Center West
      • Columbus, Ohio, United States, 43219
        • Suspended
        • The Mark H Zangmeister Center
      • Dayton, Ohio, United States, 45409
        • Suspended
        • Miami Valley Hospital
      • Dayton, Ohio, United States, 45415
        • Suspended
        • Miami Valley Hospital North
      • Dayton, Ohio, United States, 45415
        • Suspended
        • Dayton Physician LLC - Englewood
      • Dayton, Ohio, United States, 45409
        • Suspended
        • Premier Blood and Cancer Center
      • Delaware, Ohio, United States, 43015
        • Recruiting
        • Delaware Health Center-Grady Cancer Center
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Delaware, Ohio, United States, 43015
        • Recruiting
        • Grady Memorial Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Dublin, Ohio, United States, 43016
        • Recruiting
        • Columbus Oncology and Hematology Associates
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Dublin, Ohio, United States, 43016
        • Recruiting
        • Dublin Methodist Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Findlay, Ohio, United States, 45840
        • Suspended
        • Blanchard Valley Hospital
      • Findlay, Ohio, United States, 45840
        • Suspended
        • Orion Cancer Care
      • Findlay, Ohio, United States, 45840
        • Suspended
        • Armes Family Cancer Center
      • Franklin, Ohio, United States, 45005-1066
        • Suspended
        • Atrium Medical Center-Middletown Regional Hospital
      • Franklin, Ohio, United States, 45005
        • Suspended
        • Dayton Physicians LLC-Atrium
      • Gahanna, Ohio, United States, 43230
        • Suspended
        • Central Ohio Breast and Endocrine Surgery
      • Greenville, Ohio, United States, 45331
        • Suspended
        • Dayton Physicians LLC-Wayne
      • Greenville, Ohio, United States, 45331
        • Suspended
        • Wayne Hospital
      • Greenville, Ohio, United States, 45331
        • Suspended
        • Miami Valley Cancer Care and Infusion
      • Grove City, Ohio, United States, 43123
        • Suspended
        • Mount Carmel Grove City Hospital
      • Grove City, Ohio, United States, 43123
        • Suspended
        • Zangmeister Center Grove City
      • Kettering, Ohio, United States, 45409
        • Suspended
        • Greater Dayton Cancer Center
      • Kettering, Ohio, United States, 45429
        • Suspended
        • Kettering Medical Center
      • Lancaster, Ohio, United States, 43130
        • Suspended
        • Fairfield Medical Center
      • Lima, Ohio, United States, 45801
        • Suspended
        • Saint Rita's Medical Center
      • Mansfield, Ohio, United States, 44903
        • Recruiting
        • OhioHealth Mansfield Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Marietta, Ohio, United States, 45750
        • Suspended
        • Marietta Memorial Hospital
      • Marion, Ohio, United States, 43302
        • Recruiting
        • OhioHealth Marion General Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Marysville, Ohio, United States, 43040
        • Suspended
        • Memorial Hospital
      • Maumee, Ohio, United States, 43537
        • Suspended
        • Toledo Clinic Cancer Centers-Maumee
      • Mayfield Heights, Ohio, United States, 44124
        • Active, not recruiting
        • UH Seidman Cancer Center at Landerbrook Health Center
      • Mount Vernon, Ohio, United States, 43050
        • Suspended
        • Knox Community Hospital
      • New Albany, Ohio, United States, 43054
        • Suspended
        • Mount Carmel New Albany Surgical Hospital
      • Newark, Ohio, United States, 43055
        • Suspended
        • Newark Radiation Oncology
      • Newark, Ohio, United States, 43055
        • Suspended
        • Licking Memorial Hospital
      • Parma, Ohio, United States, 44129
        • Active, not recruiting
        • University Hospitals Parma Medical Center
      • Perrysburg, Ohio, United States, 43551
        • Suspended
        • Mercy Health - Perrysburg Hospital
      • Pickerington, Ohio, United States, 43147
        • Recruiting
        • OhioHealth Pickerington Methodist Hospital
        • Contact:
        • Principal Investigator:
          • Yvonne A. Efebera
      • Portsmouth, Ohio, United States, 45662
        • Suspended
        • Southern Ohio Medical Center
      • Springfield, Ohio, United States, 45504
        • Suspended
        • Springfield Regional Cancer Center
      • Springfield, Ohio, United States, 45504
        • Suspended
        • Springfield Regional Medical Center
      • Toledo, Ohio, United States, 43623
        • Suspended
        • Mercy Health - Saint Anne Hospital
      • Toledo, Ohio, United States, 43623
        • Suspended
        • Toledo Clinic Cancer Centers-Toledo
      • Toledo, Ohio, United States, 43608
        • Suspended
        • Mercy Health - Saint Vincent Hospital
      • Toledo, Ohio, United States, 43623
        • Suspended
        • Mercy Health Sylvania Radiation Oncology Center
      • Troy, Ohio, United States, 45373
        • Suspended
        • Upper Valley Medical Center
      • Troy, Ohio, United States, 45373
        • Suspended
        • Dayton Physicians LLC - Troy
      • Wadsworth, Ohio, United States, 44281
        • Active, not recruiting
        • University Hospitals Sharon Health Center
      • Warren, Ohio, United States, 44484
        • Suspended
        • Saint Joseph Warren Hospital
      • West Chester, Ohio, United States, 45069
        • Suspended
        • University of Cincinnati Cancer Center-West Chester
      • Westerville, Ohio, United States, 43081
        • Suspended
        • Saint Ann's Hospital
      • Westerville, Ohio, United States, 43082
        • Recruiting
        • OhioHealth Westerville Medical Campus/Westerville Cancer Center
        • Principal Investigator:
          • Yvonne A. Efebera
        • Contact:
      • Westlake, Ohio, United States, 44145
        • Active, not recruiting
        • UH Seidman Cancer Center at Saint John Medical Center
      • Wilmington, Ohio, United States, 45177
        • Suspended
        • Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center
      • Youngstown, Ohio, United States, 44501
        • Suspended
        • Saint Elizabeth Youngstown Hospital
      • Zanesville, Ohio, United States, 43701
        • Suspended
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73120
        • Recruiting
        • Mercy Hospital Oklahoma City
        • Principal Investigator:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Phone Number: 405-752-3402
    • Oregon
      • Baker City, Oregon, United States, 97814
        • Recruiting
        • Saint Alphonsus Cancer Care Center-Baker City
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Bend, Oregon, United States, 97701
        • Suspended
        • Saint Charles Health System
      • Clackamas, Oregon, United States, 97015
        • Suspended
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, United States, 97015
        • Suspended
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, United States, 97420
        • Suspended
        • Bay Area Hospital
      • Hood River, Oregon, United States, 97031
        • Suspended
        • Providence Hood River Memorial Hospital
      • Newberg, Oregon, United States, 97132
        • Suspended
        • Providence Newberg Medical Center
      • Ontario, Oregon, United States, 97914
        • Recruiting
        • Saint Alphonsus Cancer Care Center-Ontario
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Oregon City, Oregon, United States, 97045
        • Suspended
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, United States, 97239
        • Suspended
        • Oregon Health and Science University
      • Portland, Oregon, United States, 97213
        • Suspended
        • Providence Portland Medical Center
      • Portland, Oregon, United States, 97225
        • Suspended
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, United States, 97756
        • Suspended
        • Saint Charles Health System-Redmond
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Recruiting
        • Lehigh Valley Hospital-Cedar Crest
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Bethlehem, Pennsylvania, United States, 18017
        • Recruiting
        • Lehigh Valley Hospital - Muhlenberg
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Chadds Ford, Pennsylvania, United States, 19317
        • Active, not recruiting
        • Christiana Care Health System-Concord Health Center
      • Danville, Pennsylvania, United States, 17822
        • Suspended
        • Geisinger Medical Center
      • Dickson City, Pennsylvania, United States, 18519
        • Suspended
        • Geisinger Cancer Center Dickson City
      • East Stroudsburg, Pennsylvania, United States, 18301
        • Recruiting
        • Pocono Medical Center
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Harrisburg, Pennsylvania, United States, 17111
        • Recruiting
        • Penn State Health Medical Group - Andrews Patel Hematology/Oncology East
        • Principal Investigator:
          • Kevin Rakszawski
        • Contact:
          • Site Public Contact
          • Phone Number: 717-526-1030
      • Hazleton, Pennsylvania, United States, 18201
        • Recruiting
        • Lehigh Valley Hospital-Hazleton
        • Contact:
        • Principal Investigator:
          • Elie G. Dib
      • Hazleton, Pennsylvania, United States, 18201
        • Suspended
        • Geisinger Medical Center-Cancer Center Hazleton
      • Hershey, Pennsylvania, United States, 17033-0850
        • Suspended
        • Penn State Milton S Hershey Medical Center
      • Lewisburg, Pennsylvania, United States, 17837
        • Suspended
        • Geisinger Medical Oncology-Lewisburg
      • Philadelphia, Pennsylvania, United States, 19107
        • Suspended
        • Thomas Jefferson University Hospital
      • Pottsville, Pennsylvania, United States, 17901
        • Suspended
        • Geisinger Cancer Services-Pottsville
      • Reading, Pennsylvania, United States, 19605
        • Recruiting
        • Penn State Health Saint Joseph Medical Center
        • Principal Investigator:
          • Kevin Rakszawski
        • Contact:
      • Scranton, Pennsylvania, United States, 18510
        • Suspended
        • Community Medical Center
      • West Reading, Pennsylvania, United States, 19611
        • Suspended
        • Reading Hospital
      • Wilkes-Barre, Pennsylvania, United States, 18711
        • Suspended
        • Geisinger Wyoming Valley/Henry Cancer Center
    • Rhode Island
      • Westerly, Rhode Island, United States, 02891
        • Suspended
        • Smilow Cancer Hospital Care Center - Westerly
    • South Carolina
      • Charleston, South Carolina, United States, 29401
        • Recruiting
        • Ralph H Johnson VA Medical Center
        • Contact:
        • Principal Investigator:
          • Oleksandra Lupak
      • Charleston, South Carolina, United States, 29425
        • Suspended
        • Medical University of South Carolina
      • Greenville, South Carolina, United States, 29601
        • Active, not recruiting
        • Saint Francis Hospital
      • Greenville, South Carolina, United States, 29607
        • Active, not recruiting
        • Saint Francis Cancer Center
    • South Dakota
      • Rapid City, South Dakota, United States, 57701
        • Suspended
        • Rapid City Regional Hospital
      • Sioux Falls, South Dakota, United States, 57105
        • Active, not recruiting
        • Avera Cancer Institute
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Suspended
        • Vanderbilt University/Ingram Cancer Center
    • Texas
      • Bryan, Texas, United States, 77802
        • Suspended
        • Saint Joseph Regional Cancer Center
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Suspended
        • Huntsman Cancer Institute/University of Utah
    • Vermont
      • Burlington, Vermont, United States, 05405
        • Suspended
        • University of Vermont and State Agricultural College
      • Burlington, Vermont, United States, 05401
        • Suspended
        • University of Vermont Medical Center
      • White River Junction, Vermont, United States, 05009
        • Recruiting
        • White River Junction Veteran Administration Medical Center
        • Contact:
          • Site Public Contact
          • Phone Number: 866-687-8387
        • Principal Investigator:
          • Britt H. Olmsted
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • Suspended
        • University of Virginia Cancer Center
      • Fairfax, Virginia, United States, 22031
        • Active, not recruiting
        • Inova Schar Cancer Institute
      • Falls Church, Virginia, United States, 22042
        • Active, not recruiting
        • Inova Fairfax Hospital
      • Lynchburg, Virginia, United States, 24501
        • Suspended
        • Centra Alan B Pearson Regional Cancer Center
      • Richmond, Virginia, United States, 23229
        • Suspended
        • Virginia Cancer Institute
      • Richmond, Virginia, United States, 23298
        • Suspended
        • VCU Massey Comprehensive Cancer Center
      • South Hill, Virginia, United States, 23970
        • Suspended
        • VCU Community Memorial Health Center
    • Washington
      • Aberdeen, Washington, United States, 98520
        • Suspended
        • Providence Regional Cancer System-Aberdeen
      • Bellingham, Washington, United States, 98225
        • Suspended
        • PeaceHealth Saint Joseph Medical Center
      • Burien, Washington, United States, 98166
        • Suspended
        • Highline Medical Center-Main Campus
      • Centralia, Washington, United States, 98531
        • Suspended
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, United States, 98026
        • Suspended
        • Swedish Cancer Institute-Edmonds
      • Enumclaw, Washington, United States, 98022
        • Suspended
        • Saint Elizabeth Hospital
      • Everett, Washington, United States, 98201
        • Suspended
        • Providence Regional Cancer Partnership
      • Federal Way, Washington, United States, 98003
        • Suspended
        • Saint Francis Hospital
      • Issaquah, Washington, United States, 98029
        • Suspended
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, United States, 99336
        • Suspended
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, United States, 98503
        • Suspended
        • Providence Regional Cancer System-Lacey
      • Lakewood, Washington, United States, 98499
        • Suspended
        • Saint Clare Hospital
      • Longview, Washington, United States, 98632
        • Suspended
        • PeaceHealth Saint John Medical Center
      • Mount Vernon, Washington, United States, 98274
        • Suspended
        • Skagit Regional Health Cancer Care Center
      • Poulsbo, Washington, United States, 98370
        • Active, not recruiting
        • Harrison HealthPartners Hematology and Oncology-Poulsbo
      • Seattle, Washington, United States, 98104
        • Suspended
        • Pacific Gynecology Specialists
      • Seattle, Washington, United States, 98107
        • Suspended
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, United States, 98122-5711
        • Suspended
        • Swedish Medical Center-Cherry Hill
      • Seattle, Washington, United States, 98122
        • Suspended
        • Swedish Medical Center-First Hill
      • Sedro-Woolley, Washington, United States, 98284
        • Suspended
        • PeaceHealth United General Medical Center
      • Shelton, Washington, United States, 98584
        • Suspended
        • Providence Regional Cancer System-Shelton
      • Silverdale, Washington, United States, 98383
      • Spokane, Washington, United States, 99202
        • Suspended
        • Cancer Care Northwest - Spokane South
      • Spokane, Washington, United States, 99216
        • Suspended
        • Cancer Care Northwest-Valley
      • Spokane, Washington, United States, 99218
        • Suspended
        • Cancer Care Northwest-North Spokane
      • Tacoma, Washington, United States, 98405
        • Suspended
        • Franciscan Research Center-Northwest Medical Plaza
      • Tacoma, Washington, United States, 98405
        • Suspended
        • Northwest Medical Specialties PLLC
      • Vancouver, Washington, United States, 98664
        • Suspended
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, United States, 99362
        • Suspended
        • Providence Saint Mary Regional Cancer Center
      • Yelm, Washington, United States, 98597
        • Suspended
        • Providence Regional Cancer System-Yelm
    • West Virginia
      • Charleston, West Virginia, United States, 25304
        • Active, not recruiting
        • West Virginia University Charleston Division
    • Wisconsin
      • Appleton, Wisconsin, United States, 54911
        • Recruiting
        • ThedaCare Regional Cancer Center
        • Contact:
        • Principal Investigator:
          • Yazhini Vallatharasu
      • Appleton, Wisconsin, United States, 54915
        • Suspended
        • Ascension Saint Elizabeth Hospital
      • Baraboo, Wisconsin, United States, 53913
        • Active, not recruiting
        • SSM Health Dean Medical Group - Baraboo
      • Brookfield, Wisconsin, United States, 53045
        • Suspended
        • Ascension Southeast Wisconsin Hospital - Elmbrook Campus
      • Burlington, Wisconsin, United States, 53105
        • Suspended
        • Aurora Cancer Care-Southern Lakes VLCC
      • Chilton, Wisconsin, United States, 53014
        • Suspended
        • Ascension Calumet Hospital
      • Chippewa Falls, Wisconsin, United States, 54729
        • Suspended
        • Marshfield Clinic-Chippewa Center
      • Cudahy, Wisconsin, United States, 53110
        • Suspended
        • Aurora Saint Luke's South Shore
      • Eau Claire, Wisconsin, United States, 54701
        • Suspended
        • Marshfield Medical Center-EC Cancer Center
      • Eau Claire, Wisconsin, United States, 54701
        • Active, not recruiting
        • HSHS Sacred Heart Hospital
      • Franklin, Wisconsin, United States, 53132
        • Suspended
        • Ascension Saint Francis - Reiman Cancer Center
      • Franklin, Wisconsin, United States, 53132
        • Suspended
        • Ascension Southeast Wisconsin Hospital - Franklin
      • Germantown, Wisconsin, United States, 53022
        • Suspended
        • Aurora Health Care Germantown Health Center
      • Grafton, Wisconsin, United States, 53024
        • Suspended
        • Aurora Cancer Care-Grafton
      • Green Bay, Wisconsin, United States, 54301
        • Recruiting
        • Saint Vincent Hospital Cancer Center Green Bay
        • Principal Investigator:
          • Brian L. Burnette
        • Contact:
      • Green Bay, Wisconsin, United States, 54303
        • Recruiting
        • Saint Vincent Hospital Cancer Center at Saint Mary's
        • Principal Investigator:
          • Brian L. Burnette
        • Contact:
      • Green Bay, Wisconsin, United States, 54311
        • Suspended
        • Aurora BayCare Medical Center
      • Janesville, Wisconsin, United States, 53546
        • Active, not recruiting
        • SSM Health Dean Medical Group - Janesville
      • Johnson Creek, Wisconsin, United States, 53038
        • Suspended
        • University of Wisconsin Carbone Cancer Center - Johnson Creek
      • Kenosha, Wisconsin, United States, 53142
        • Suspended
        • Aurora Cancer Care-Kenosha South
      • La Crosse, Wisconsin, United States, 54601
        • Recruiting
        • Gundersen Lutheran Medical Center
        • Contact:
        • Principal Investigator:
          • Kurt Oettel
      • La Crosse, Wisconsin, United States, 54601
        • Suspended
        • Mayo Clinic Health System-Franciscan Healthcare
      • Ladysmith, Wisconsin, United States, 54848
        • Suspended
        • Marshfield Medical Center - Ladysmith
      • Madison, Wisconsin, United States, 53705
        • Recruiting
        • William S Middleton VA Medical Center
        • Principal Investigator:
          • Christopher D. Fletcher
        • Contact:
          • Site Public Contact
          • Phone Number: 17007 608-256-1901
      • Madison, Wisconsin, United States, 53792
        • Recruiting
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Principal Investigator:
          • Timothy M. Schmidt
        • Contact:
      • Madison, Wisconsin, United States, 53715
        • Active, not recruiting
        • SSM Health Dean Medical Group - South Madison Campus
      • Madison, Wisconsin, United States, 53718
        • Suspended
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Marinette, Wisconsin, United States, 54143
        • Suspended
        • Aurora Bay Area Medical Group-Marinette
      • Marshfield, Wisconsin, United States, 54449
        • Suspended
        • Marshfield Medical Center-Marshfield
      • Mequon, Wisconsin, United States, 53097
        • Suspended
        • Ascension Columbia Saint Mary's Hospital Ozaukee
      • Milwaukee, Wisconsin, United States, 53210
        • Suspended
        • Ascension Southeast Wisconsin Hospital - Saint Joseph Campus
      • Milwaukee, Wisconsin, United States, 53211
        • Suspended
        • Ascension Columbia Saint Mary's Hospital - Milwaukee
      • Milwaukee, Wisconsin, United States, 53215
        • Suspended
        • Ascension Saint Francis Hospital
      • Milwaukee, Wisconsin, United States, 53209
        • Suspended
        • Aurora Cancer Care-Milwaukee
      • Milwaukee, Wisconsin, United States, 53215
        • Suspended
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, United States, 53233
        • Suspended
        • Aurora Sinai Medical Center
      • Minocqua, Wisconsin, United States, 54548
        • Suspended
        • Marshfield Medical Center - Minocqua
      • Mukwonago, Wisconsin, United States, 53149
        • Suspended
        • ProHealth D N Greenwald Center
      • Neenah, Wisconsin, United States, 54956
        • Recruiting
        • ThedaCare Regional Medical Center - Neenah
        • Contact:
        • Principal Investigator:
          • Yazhini Vallatharasu
      • Neillsville, Wisconsin, United States, 54456
        • Suspended
        • Marshfield Medical Center - Neillsville
      • New Richmond, Wisconsin, United States, 54017
        • Recruiting
        • Cancer Center of Western Wisconsin
        • Contact:
        • Principal Investigator:
          • David M. King
      • Oconomowoc, Wisconsin, United States, 53066
        • Suspended
        • ProHealth Oconomowoc Memorial Hospital
      • Oconto Falls, Wisconsin, United States, 54154
        • Recruiting
        • Saint Vincent Hospital Cancer Center at Oconto Falls
        • Principal Investigator:
          • Brian L. Burnette
        • Contact:
      • Oshkosh, Wisconsin, United States, 54904
        • Suspended
        • Ascension Mercy Hospital
      • Oshkosh, Wisconsin, United States, 54904
        • Suspended
        • Vince Lombardi Cancer Clinic - Oshkosh
      • Racine, Wisconsin, United States, 53405
        • Suspended
        • Ascension All Saints Hospital
      • Racine, Wisconsin, United States, 53406
        • Suspended
        • Aurora Cancer Care-Racine
      • Rice Lake, Wisconsin, United States, 54868
        • Suspended
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, United States, 53081
        • Suspended
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Stevens Point, Wisconsin, United States, 54482
        • Suspended
        • Marshfield Medical Center-River Region at Stevens Point
      • Sturgeon Bay, Wisconsin, United States, 54235-1495
        • Recruiting
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
        • Principal Investigator:
          • Brian L. Burnette
        • Contact:
      • Summit, Wisconsin, United States, 53066
        • Suspended
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, United States, 54241
        • Suspended
        • Vince Lombardi Cancer Clinic-Two Rivers
      • Waukesha, Wisconsin, United States, 53188
        • Suspended
        • ProHealth Waukesha Memorial Hospital
      • Waukesha, Wisconsin, United States, 53188
        • Suspended
        • UW Cancer Center at ProHealth Care
      • Wausau, Wisconsin, United States, 54401
        • Suspended
        • Marshfield Clinic-Wausau Center
      • Wauwatosa, Wisconsin, United States, 53226
        • Suspended
        • Ascension Medical Group Southeast Wisconsin - Mayfair Road
      • Wauwatosa, Wisconsin, United States, 53226
        • Suspended
        • Aurora Cancer Care-Milwaukee West
      • West Allis, Wisconsin, United States, 53227
        • Suspended
        • Aurora West Allis Medical Center
      • Weston, Wisconsin, United States, 54476
        • Suspended
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, United States, 54494
        • Suspended
        • Marshfield Clinic - Wisconsin Rapids Center
    • Wyoming
      • Cheyenne, Wyoming, United States, 82001
        • Suspended
        • Memorial Hospital of Laramie County
      • Cody, Wyoming, United States, 82414
        • Suspended
        • Billings Clinic-Cody
      • Sheridan, Wyoming, United States, 82801
        • Suspended
        • Welch Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • STEP 0 - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
  • STEP 0 - Patient must have newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria
  • STEP 0 - Patient must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of RevREMS

  • STEP 0 - Patient must be able to undergo diagnostic bone marrow aspirate following preregistration.

    • NOTE: Bone marrow aspirate specimen must be submitted to Adaptive Biotechnologies for clonoSEQ Assay
    • NOTE: Adaptive Biotechnologies will release results to the diagnostic Portal from the Clonality (ID) test within fourteen (14) days of receipt and reconciliation of fresh bone marrow specimen to the submitting institution
  • STEP 1 - Patient must meet all eligibility criteria in STEP 0 with exception of allergy requirement
  • STEP 1 - Institution must have received the Clonality (ID) test results from Adaptive Biotechnologies and dominant sequences were identified

  • STEP 1 - Patient must have standard risk MM as defined by the Revised International Staging System (RISS) stage I or II

    • NOTE: R-ISS stage is based on serum beta2 microglobulin, albumin and lactate dehydrogenase (LDH) levels along with presence of chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH). Presence of del(17p), t(4;14), and/or t(14;16) is considered high risk and absence of these, including any other findings, are standard risk

    • R-ISS stage

      • Stage I: ISS stage I [beta2 macroglobulin < 3.5 mg/L, albumin > 3.5 g/dL] AND standard-risk CA AND normal LDH
      • Stage II: Not R-ISS stage I or III
      • Stage III: ISS stage III [beta2 macroglobulin > 5.5 mg/L] AND high-risk CA OR high LDH (> upper limit of normal) [patients with stage III are ineligible]

  • STEP 1 - Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to registration:

    • >= 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis
    • >= 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis
    • Involved free light chain >= 10 mg/dL or >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (< 0.26 or > 1.65)
    • Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)

  • STEP 1 - Patients must have a serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay performed within 28 days prior to registration. In addition, a bone marrow biopsy and/or aspirate is required within 28 days if bone marrow is being followed for response

    • NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hr. Please note that if both serum and urine M-components are present, both must be followed in order to evaluate response
    • NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine. Measurable disease in the serum is defined as having a serum M-spike >= 1 g/dL. Measurable disease in the urine is defined as having a urine M-spike >= 200 mg/24 hr
  • STEP 1 - Calculated creatinine clearance > 30 mL/min (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Untransfused platelet count >= 75,000/mm^3 (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Patient must have received no more than one cycle (28 days or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma. Patient must not have been exposed to daratumumab for treatment of symptomatic myeloma. Prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts meet the study requirements. Radiation treatment must be completed at least 14 days prior to Step 1 registration
  • STEP 1 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
  • STEP 1 - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • STEP 1 - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • STEP 1 - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • STEP 1 - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients must not have evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within 6 months prior to Step 1 registration
  • STEP 1 - Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
  • STEP 1 - Patients with a history of chronic obstructive pulmonary disease (COPD) must have FEV1 testing done within 28 days prior to Step 1 registration and the forced expiratory volume in 1 second (FEV1) must be > 50% of predicted normal
  • STEP 2 - Institution must have received Tracking (MRD) test results from Adaptive Biotechnologies
  • STEP 2 - Patient must have completed the Step 1 Induction phase of this protocol without experiencing progression
  • STEP 2 - Patient must be registered to Step 2 within 8 weeks of completing Step 1 Induction Treatment, counting from last day of completion of last cycle
  • STEP 2 - Patient must have an ECOG performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
  • STEP 2 - Any adverse event(s) related to Step 1 Induction Treatment must have resolved to grade 2 or less
  • STEP 2 - Hemoglobin >= 8 g/dL (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Platelet count >= 50,000/mm^3 (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Calculated creatinine clearance >= 30 mL/min (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Total bilirubin =< 1.5 x ULN (Institutional upper limit of normal) (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - ALT and AST < 3 x ULN (obtained within 14 days prior to Step 2 randomization)

Exclusion Criteria:

  • STEP 0 - Patient must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products

  • STEP 1 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 1 registration to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

    • Has achieved menarche at some point,
    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • STEP 1 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment
  • STEP 1 - Patient must not have peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain at time of Step 1 registration
  • STEP 1 - Patient must not have any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol

  • STEP 1 - Patient must not have moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification

    • NOTE: Patients who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to register

  • STEP 1 - Patient must not receive any other concurrent chemotherapy, or any ancillary therapy considered investigational while on this protocol

    • NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
  • STEP 2 - Patient must not have received any non-protocol therapy outside of the assigned Step 1 Induction treatment including stem cell transplant

  • STEP 2 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 2 randomization to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

    • Has achieved menarche at some point,
    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  • STEP 2 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).

Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm A (daratumumab, lenalidomide, dexamethasone)
INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
  • Quality of Life Assessment
Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501
Drug: Dexamethasone
Given PO
Other Names:
  • Decadron
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron DP
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorene
  • Deronil
  • Desamethasone
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorene
  • Dexalocal
  • Dexamecortin
  • Dexameth
  • Dexamethasone Intensol
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Methylfluorprednisolone
  • Millicorten
  • Mymethasone
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazone
  • ZoDex
Biological: Daratumumab and Hyaluronidase-fihj
Given SC
Other Names:
  • DARA Co-formulated with rHuPH20
  • DARA/rHuPH20
  • Daratumumab + rHuPH20
  • Daratumumab with rHuPH20
  • Daratumumab-rHuPH20
  • Daratumumab/Hyaluronidase-fihj
  • Daratumumab/rHuPH20 Co-formulation
  • Darzalex Faspro
  • Darzalex/rHuPH20
  • HuMax-CD38-rHuPH20
  • Recombinant Human Hyaluronidase Mixed with Daratumumab
Experimental: Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)

CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
  • Quality of Life Assessment
Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501
Drug: Dexamethasone
Given PO
Other Names:
  • Decadron
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron DP
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorene
  • Deronil
  • Desamethasone
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorene
  • Dexalocal
  • Dexamecortin
  • Dexameth
  • Dexamethasone Intensol
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Methylfluorprednisolone
  • Millicorten
  • Mymethasone
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazone
  • ZoDex
Drug: Bortezomib
Given SC
Other Names:
  • Velcade
  • MLN341
  • PS-341
  • LDP 341
  • [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid
  • PS341
Biological: Daratumumab and Hyaluronidase-fihj
Given SC
Other Names:
  • DARA Co-formulated with rHuPH20
  • DARA/rHuPH20
  • Daratumumab + rHuPH20
  • Daratumumab with rHuPH20
  • Daratumumab-rHuPH20
  • Daratumumab/Hyaluronidase-fihj
  • Daratumumab/rHuPH20 Co-formulation
  • Darzalex Faspro
  • Darzalex/rHuPH20
  • HuMax-CD38-rHuPH20
  • Recombinant Human Hyaluronidase Mixed with Daratumumab
Active Comparator: Arm C (daratumumab, lenalidomide, dexamethasone)

CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
  • Quality of Life Assessment
Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501
Drug: Dexamethasone
Given PO
Other Names:
  • Decadron
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycadron
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron DP
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorene
  • Deronil
  • Desamethasone
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorene
  • Dexalocal
  • Dexamecortin
  • Dexameth
  • Dexamethasone Intensol
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Methylfluorprednisolone
  • Millicorten
  • Mymethasone
  • Orgadrone
  • Spersadex
  • TaperDex
  • Visumetazone
  • ZoDex
Biological: Daratumumab and Hyaluronidase-fihj
Given SC
Other Names:
  • DARA Co-formulated with rHuPH20
  • DARA/rHuPH20
  • Daratumumab + rHuPH20
  • Daratumumab with rHuPH20
  • Daratumumab-rHuPH20
  • Daratumumab/Hyaluronidase-fihj
  • Daratumumab/rHuPH20 Co-formulation
  • Darzalex Faspro
  • Darzalex/rHuPH20
  • HuMax-CD38-rHuPH20
  • Recombinant Human Hyaluronidase Mixed with Daratumumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Consolidation overall survival
Time Frame: Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years
Will be estimated using the Kaplan-Meier (KM) method and compared using a stratified log-rank test. Stratified cox proportional hazards regression will produce treatment hazard ratio (bortezomib, daratumumab and hyaluronidase-fihj (daratumumab), lenalidomide and dexamethasone [Btz-DRd] then daratumumab, lenalidomide and dexamethasone [DRd] then daratumumab and lenalidomide [DR]).
Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Consolidation progression-free survival
Time Frame: Time from Step 2 randomization at the start of consolidation until the earlier of progression or death due to any cause, assessed up to 15 years
Patients alive without disease progression will be censored at date of last disease evaluation. Only deaths that occur within 3 months of the last disease evaluation are considered events.
Time from Step 2 randomization at the start of consolidation until the earlier of progression or death due to any cause, assessed up to 15 years
Incidence of adverse events
Time Frame: During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
Incidence of grade 3 or higher non-hematologic adverse events
Time Frame: During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
Incidence of grade 3 or higher adverse events
Time Frame: During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
Best response
Time Frame: During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
During induction, consolidation, and maintenance; a period of up to 42 months (9 months of induction, 9 months of consolidation, and up to 2 years of maintenance).
FACT-Ntx TOI recovery rate (Patient reported outcome [PRO])
Time Frame: From end of induction through consolidation up to 1 year of maintenance, up to 21 weeks
Defined as the proportion of patients with the FACT-Ntx TOI score returning to baseline level reached at consolidation randomization after experiencing a MID decrease while on up to 1 year of maintenance.
From end of induction through consolidation up to 1 year of maintenance, up to 21 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Functional Assessment of Cancer Therapy - Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) score (Patient reported outcome)
Time Frame: From end of induction to after completion of 9 cycles of consolidation, a period of approximately 36 weeks (9 months)
Calculated as the difference after completion of 9 cycles of consolidation therapy from end of induction. Scores can range from a minimum of 0 and a maximum of 44. A higher score on this assessment means a worse outcome.
From end of induction to after completion of 9 cycles of consolidation, a period of approximately 36 weeks (9 months)
Levels and changes of FACT-General (G) (physical well-being [PWB] + functional well-being [FWB]) score (PRO)
Time Frame: From the end of induction through 1 year of maintenance, 21 weeks
The FACT-G is a single outcome measure made up of the PWB and FWB components. Scores range from a minimum of 0 and a maximum of 56. For this assessment, a higher score means a better outcome.
From the end of induction through 1 year of maintenance, 21 weeks
Presence, frequency, interference, amount and/or severity of select PRO- Common Terminology Criteria for Adverse Events (CTCAEs) (PRO)
Time Frame: Up to 15 years
Presence, frequency, interference, amount and/or severity of select PRO-CTCAEs tabulated at each measurement.
Up to 15 years
Comparison of selected PRO-CTCAEs with provider obtained assessment of same CTCAE items (PRO)
Time Frame: Up to 15 years
Up to 15 years
PRO compliance rate
Time Frame: Up to 15 years
Defined as the proportion of patients who submit the given PRO instrument among those eligible at each time point which excludes those missing by design (due to death or disease progression, early treatment discontinuation).
Up to 15 years
PRO completion rate
Time Frame: Up to 15 years
Defined as the proportion of patients who complete given PRO instrument based on the instrument's scoring system among those eligible at each time point.
Up to 15 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Shaji K Kumar, ECOG-ACRIN Cancer Research Group

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 24, 2021

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

September 16, 2020

First Submitted That Met QC Criteria

September 22, 2020

First Posted (Actual)

September 28, 2020

Study Record Updates

Last Update Posted (Actual)

May 15, 2026

Last Update Submitted That Met QC Criteria

May 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EAA181 (Other Identifier: CTEP)
  • U10CA180820 (U.S. NIH Grant/Contract)
  • NCI-2020-06647 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Plasma Cell Myeloma

Clinical Trials on Quality-of-Life Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe